Pharmaceutical Executive
Brussels, Belgium-Tackling communicable diseases such as malaria and tuberculosis and making pregnancy and childbirth safer are priorities for the restructured Afghan health ministry, according to World Health Organization officials.
Brussels, Belgium-Tackling communicable diseases such as malaria and tuberculosis and making pregnancy and childbirth safer are priorities for the restructured Afghan health ministry, according to World Health Organization officials.
WHO, the United Nations Children's Fund, and non-governmental organizations have launched an appeal for nearly $130 million for immediate reconstruction of the war-torn country's health system, including vital medicines.
"Developing a functional healthcare system must be a top priority in the reconstruction of Afghanistan," says Dr. Mohammed Jama, WHO regional coordinator for the Afghanistan crisis. "As long as hundreds of thousands of Afghans continue to die from preventable diseases, a stable future for the country cannot be guaranteed."
A WHO mission to Afghanistan revealed a shortage of essential medicines that donations have only marginally improved in recent months. WHO is asking for $25 million to set up medical stores across the country.
Other priorities include the integrated management of childhood illnesses, the establishment of mental health services, and a safe blood transfusion service. "This package of basic services is designed to offer the basis of acceptable healthcare in Afghanistan," says Dr. Said Youssouf, WHO representative in Afghanistan.
The WHO appeal would amount to spending slightly more than $5 per person per year in Afghanistan. The organization estimates that $34 per person per year is needed for basic health services, but the present Afghani health infrastructure cannot handle such large amounts.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.